Life Sciences Archive » March, 2009

Life Sciences - March, 2009

179 articles

• $185M Damage Award To Bard Not 'Monstrous': Judge
• FDA Wants Unapproved Painkillers Taken Off Shelves
• Cordis, Boston Sci. Infringed Stents: Fed. Circ.
• IBM, Others Sued Over Database Patent
• Bayer Wants More Fraud Claims Nixed In Trasylol MDL
• Schering Sales Reps Not Exempt Under FLSA: Judge
• 5th Circ. Lets Lilly Off Hook In Zyprexa Suicide
• AstraZeneca Sales Reps Exempt From OT: Judge
• Life Technologies, GE Settle DNA Kit Suit
• Securities Suit V. Axonyx Over Alzheimer's Drug Nixed
• Adapting Private Business To Climate Change
• Caraco Recalls Digoxin Over Irregular Dosage Fears
• Watson Scores Win In J&J Patent Spat Over Concerta
• CORRECTED: 11th Circ. Sides With Feds In Endotec Device Suit
• J&J Units Resolve Spat Over Razadyne-ER Patent
• GE Told To Pay $11.4M In False Advertising Case
• Acacia Unit Sues P&G Over Videoconference Patent
• PTO Rules For Smith & Nephew In Suture Patent Fight
• Medtronic Recalls Brain Catheters Over Malfunctions
• DOJ Probing Par Over Megace Off-Label Marketing
• Are 'Reverse Payments' Becoming More Reasonable?
• Judge Denies Class Cert. In Funeral Home Cases
• Mich. House Votes To Repeal Drugmaker Immunity
• Biolitec AG Escapes AMS Laser Patent Suit
• Doctors Told To Pay State Farm $15M In Fraud Case
• Senate Biologics Bill Draws Industry Ire
• BMS To Pay $2.1M To Settle FTC's Plavix Claims
• Dancer, Printers Settle With SEC Over Trading Scam
• FTC Seeks More Info On Thoratec, HeartWare Merger
• Scams, Pay-For-Delay In FTC's Crosshairs This Year
• Law Preempts State Vaccine Liability Claims: 3rd Circ.
• Merck, Gnosis Settle Vitamin False Marketing Case
• Revival Of USPTO Rules Spurs Call For Appeal
• Vista, Others Drop Claims In Neurontin Case V. Pfizer
• Investor Asks To Replead Medtronic Securities Suit
• House Bill Would Ban Reverse Payment Settlements
• Lilly Loses Round Over Depositions In Zyprexa MDL
• Medco Unit Poached Rival's Customers: Suit
• Synthes Bone Plate Suit Stayed For Patent Re-Exam
• Medtronic Wins Stay In Abbott Stent Patent Suit
• Lannett, KV Bury Hatchet Over Vitamin Patents
• Lilly Can't Depose Mont. Docs In Zyprexa Suit: Judge
• Sens. Make Plea For Compromise On Patent Reform
• IP Partners Leave Lahive For McCarter & English
• Most Digital Firms License, Enforce IP Rights: Survey
• Teva Infringes Patents For Antibiotic Cubicin: Suit
• Wyeth Loses Bid To Extend Exclusivity For Cydectin
• Watson Recalls Irregular Heartbeat Drug
• CVT Shareholders Sue To Stop $1.4B Biotech Merger
• Merck Loses JMOL Bid In ERISA Suit Over Vioxx Errors
• $14M Settlement Reached In Dura Securities Suit
• Generics Behaving Badly: Carve Outs, Off-Label Uses
• Organon Denied Ex Parte Contact In NuvaRing MDL
• Sepracor Sues Generics Makers Over Lunesta Patents
• Most Of ERISA Securities Case V. Pfizer Moves Ahead
• Court Won't Vacate Preemption Ruling In Redux Suit
• AMS Prostate Laser Not Infringed By Biolitec: Court
• J&J Unit Revises Label For Evra Patch In Canada
• Hogan Denies Conflict Of Interest In IP Suit
• CORRECTED: Boston Scientific, Radiologist Settle Stent Patent Suit
• High Court Won't Hear Apotex's Risperdal Appeal
• Tafas V. Doll — Round II: 1 Down, 3 To Go
• Rival Biologics Bills May Determine No. Of Patent Suits
• FTC Declines To Challenge Reverse Payment Deal
• Bodee Yanks Zencore Over Blood Pressure Worries
• BD Nova Wins $5.9M In Fees In Abbott Patent Case
• Baby Bath Products Contain Formaldehyde: Suit
• Mich. Legislators Fight To Nix Drugmakers' Immunity
• Stryker, Zimmer Get Kickback Suit Dismissed
• OSI Sues Teva, Mylan Over Cancer Drug Patents
• Fed. Circ. Sides With USPTO In Tafas Case
• DC's Pharmacy Benefits Disclosure Law Struck Down
• Medtronic Gets OK To Seek Review Of Stent IP Ruling
• Teva, Medicis Strike Deal On Acne Drug Solodyn
• K&L Gates Snags Synthon VP, General Counsel
• Warner Chilcott Sues Impax Again In Doryx IP Spat
• 8th Circ. Shuts Down Qui Tam Suit V. Hypoguard
• China Tests J&J Baby Products In Carcinogen Scare
• Biologics Concerns Shift From IP To Bioterrorism
• Most Of Denture Cream Suit Against GSK Tossed
• Asbestos Claims Fuel Rise In US Caseload: Report
• As 1 Roche Investor Suit Ends, Another Moves Ahead
• Baker Donelson Launches Drug And Device Group
• Pfizer In Divestiture Talks Over $68B Wyeth Merger
• Isolagen To Hand Shareholders $5.25M
• Dura To Williams: Loss Causation Threshold
• NJ Judge Rebuffs Out-Of-Pocket Vioxx Class
• Rival Biologics Bill Introduced In House
• GSK Not Liable For La. Paxil Suicide: 5th Circ.
• Genzyme Hits Impax With IP Suit Over Renagel ANDA
• Welch Allyn Pulls Defibrillators Over Low Shock Issues
• Generics, Not Reglan Cos., Had Duty To Warn: Judge
• Wellbutrin Antitrust Suit To Proceed On Most Claims
• AWP Judge Denies Bulk Of Abbott Subpoena For Docs
• Health Care Nanoscience: Regulation By Litigation
• House Told DOJ Needs Antitrust Watchdog For Banks
• New Post-Wyeth Proposed Claims Filed V. Medtronic
• Danish Drugmaker Hit With IP Suit Over Cancer Test
• Amerisource Must Pay Fees In Merger Suit: Court
• Boston Scientific Stole Stent Designs: Suit
• Shire Sues Barr Over Kidney Drug ANDA
• Vertex Pharma Acquires ViroChem For $395M
• Single European Patent Would Spur Growth: EU
• Drug Cos. Hid SSRI Risks, Paid Docs Kickbacks: Suit
• Steris Settles Class Action Over Reneged Benefits
• $46.8B Roche, Genentech Deal Ends Shareholder Suit
• KV Sued Over Layoffs Following Production Freeze
• GSK Could Face Punitive Damages Over Paxil Case
• Schering-Plough To Settle Securities Suit For $165M
• Stiefel Sues Cobrek, Perrigo Over Generic Acne Drug
• Fed. Circ. Upholds $5M Patent Judgment For Alaris
• NJ Appeals Court Nixes $2.6M Ruling Against Roche
• Everett Bests Breckenridge Vitamin Patent Challenge
• Bug In Cardinal Drug Pump Could Trigger Wrong Doses
• Mylan Denied Summary Judgment In Antitrust Case
• Breast Implant Case Preempted By Riegel: Judge
• Boston Scientific, J&J Unit End Aneurysm Patent Spat
• Life Tech Targets Oxford's $173M Royalty Claim
• Seroquel MDL Judge Upholds Ban On Foreign Evidence
• Novartis Unit Settles Shareholder Action For $30M
• Grand Jury Probes Stryker Over Device Marketing
• Oxycodone Method Obvious: Fed Circ.
• Amgen Settles Ky. Medicaid Fraud Suit For $2.4M
• Covidien Tracheostomy Tube Recall Listed As Class I
• Obama Picks Public Health Expert To Head FDA
• Ex-Exec Admits Faking Cancer To Duck SEC
• Bill Aims To Create Approval Process For Biosimilars
• Plaintiff Asks To Unseal Seroquel Materials For FDA
• Judge Tosses Medtronic Securities Class Action
• Chadbourne Scores Time Warner Chief Patent Counsel
• Wyeth Loses Bid To Drop Copyright Suit Over Ads
• Medtronic Plaintiffs Can Revise Pleadings Post-Wyeth
• Genzyme Warned Over Procedures At Drug Plant
• Flonase Antitrust Plaintiffs Can Revise Class Bid
• Teva Hit With TRO Amid Lilly Evista Feud
• Dr. Reddy's Generic Doesn't Infringe Prilosec: Judge
• Dannon, Marketer Face Conditional Class In FLSA Suit
• Investor Class Approved In Suit V. Boston Scientific
• Sepracor Makes Peace With Barr Over Xopenex
• Watson To Pay Elan $18M To Settle Naprelan IP Suit
• High Court Remands Cases In Light Of Wyeth
• Fed. Circ. To Go En Banc For Method Claims Question
• Schering Merger Includes Legal Headaches For Merck
• Obama Overturns Stem Cell Research Ban
• Consequences Of Banning Reverse Payments
• Medtronic MDL Judge Refuses Recusal
• Merck, Schering Merger Puts Pressure On Regulators
• FDA Reprimands Gilead Over Letairis Statements
• Preemption Motion Withdrawn In NuvaRing MDL
• High Court Won't Hear Apotex Appeal Over Prilosec
• Plaintiffs Push To Alter Class Motions In Flonase MDL
• Volvo Execs Face Bribery Charges Over Oil-For-Food
• Fed. Circ. Rulings Shake Up IP Landscape
• Leibowitz's Past Opinions Point To Bolder FTC
• Tobacco Cos. Win Dismissal Of Medicare Tax Spat
• J&J Seeks To Halt Bausch & Lomb 'Raid On Talent'
• Genzyme Sues Lupin Over Generic Renagel
• Dems Push To Undo Riegel After Wyeth Ruling
• Applera Wins Final Judgment In Enzo Patent Fight
• DOJ Eyes Medtronic Cardiac Ablation Marketing
• Preemption After Levine: A Practical Guide
• The Audacity Of Patent Reform
• Judge Rejects Sanctions For WVa In Zyprexa MDL
• Patent Act's Damages Measure Sparks Debate
• 4th Circ. Affirms Verdict Against Pfizer In FMLA Case
• Novartis, Wyeth Unit Spar Over ReFacto Patent
• Impact Of Wyeth Decision To Be Broad, Immediate
• Lannett, Albion Spar Over Generic Vitamins
• McCain Touts Drug Imports To Lower US Costs
• High Court Rejects Preemption In Wyeth
• Amicus Brief Asks High Court To Ease Bilski Test
• Attys Seek $37.5M Of $125M Drug Prices MDL Deal
• KV Enjoined From Making, Shipping Unapproved Drugs
• Docs Show AstraZeneca Knew Of Seroquel Risks
• Judge Threatens To Sanction Firm In Prempro MDL
• GSK Offers $28M To Settle Suits Over Defective Paxil
• J&J Fined $4.5M Over False Drug Promotions
• Smithfield Drops Claims In Neurontin Class Action
• Merck Sues Sandoz Over Plan For Generic Emend